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ABSTRACT
Novel data on Multiple Sclerosis (MS) in Pakistan from leading institutes in the country was presented at the first
Pakistan Treatment in Multiple Sclerosis (PAKTRIMS) Conference, organized by the section of Neurology, department
of Medicine, Aga Khan University, Karachi on Saturday, December 18, 2021. Pakistan has been considered to have a
low prevalence of MS; however, recent research reveals that it is not as uncommon as previously believed to be in the
country. The true prevalence and incidence of MS in the country is unknown because of dearth of research. Data of
MS patients enrolled in various private and public institutes in Pakistan highlights the current treatment offered in
Pakistan for MS patients with steroids as the mainstay treatment and disease modifying therapy (DMT) mainly
including azathioprine, ocrelizumab and rituximab. Available data featuring disease progression indicates a successful
response to the treatment offered to patients with improved expanded disability status scale (EDSS) and radiological
findings. The conference was a stepping stone towards future research in Pakistan as it has highlighted further
requirements in the field of MS as far as our country is concerned. Available data majorly outlines demographic and
disease characteristics, however, there is a need for research to fill in the gap for data in reporting MS diagnosis,
treatment, and disease outcome to develop a better healthcare system geared towards MS patients in a low- and
middle-income Country (LMIC).
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INTRODUCTION
Multiple Sclerosis (MS) is an inflammatory disease of
the central nervous system (CNS) which presents with
an array of symptom.1 The disease affects an estimated
2.8 million people worldwide.2 Although Pakistan has
been considered a low prevalence country, current
research suggests MS may be more common than
previously thought.3 In Pakistan, a low- and
middle-income country (LMIC), the prevalence of MS is
approximately 10 per 100000 people. The previously
considered low prevalence could be due to lack of
awareness, unavailability of doctors or lack of
diagnostic resources.4 Research is currently being
carried out in the hopes of successfully bridging the gap
between MS patients and their access to health care in
the country.5 Although existing literature highlights
steroids as the mainstay treatment offered in Pakistan;
disease modifying therapies (DMTs) including
mitoxantrone, rituximab, beta-interferon, methotrexate,
azathioprine,
cyclophosphamide,
teriflunomide,
leflunomide, alemtuzumab, ocrelizumab, natalizumab
and fingolimod are currently available and offered for
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MS management in Pakistan.4 To address the future of
MS in Pakistan the first Pakistan Treatment in Multiple
Sclerosis (PAKTRIMS) Conference was held on
Saturday, December 18, 2021. It was organized by the
section of Neurology, department of Medicine, Aga
Khan University, Karachi. Leading neurologists from
across the country attended the conference and novel
data was presented on adult and pediatric MS patients
from various parts of the country. Neurologists
presented data from Pakistan’s topmost public
secondary and tertiary hospitals which included Sindh
Institute of Urology & Transplantation (SIUT), Dr. Ruth
K. M. Pfau Civil Hospital karachi, Pakistan Institute of
Medical Sciences (PIMS), Sheikh Khalifah Bin Zayyad
Hospital and Bolan Medical Complex Hospital. Data of
patients enrolled at the leading private secondary and
tertiary hospitals of Pakistan; Aga Khan University
Hospital and Sultan Tareen Hospital, was also
presented. The conference was a stepping stone
towards the future of MS in Pakistan. A summary of the
data presented from different institutes is summarized
in Table 1.
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Aga Khan University Hospital, Karachi

study. The most common disease course seen was
relapsing remitting MS (74.6%) followed by primary
progressive MS (15.5%). The study presented the
treatment offered to patients presenting with CNS
demyelinating diseases. Rituximab was prescribed to
9.2% patients with MS out of which 30.8% of the
patients had been switched to ocrelizumab. Treatment
for MS patients also included azathioprine (1.4%) and
plasmapheresis (2.1%). This review offers voluminous
data centering around CNS demyelinating diseases and
disease progression with treatment; however, it has a
few limitations as it did not include complications
related to MS or radiological findings of these patients.

A retrospective review was conducted at the
Department of Medicine at the Aga Khan University
Hospital in Karachi Pakistan from December 2019 to
September 2020. Medical records of all adult patients
aged 18 years and above presenting with MS according
to the McDonald’s criteria were included (6).6 This
review presents one of the largest study samples to
date of Multiple Sclerosis patients in Pakistan
highlighting demographic characteristics, disease
characteristics, readmission causes and treatment
options. A total of 163 patients were selected.
Relapsing remitting MS was the most common type of
MS found in the patients (91.4%) followed by primary
progressive MS (4.9%) and secondary progressive MS
(3.7%). Unlike previous studies, this study describes
MRI (Magnetic Resonance Images) findings in detail.
The most common finding on T2 or flair MRI scan was
presence of lesions in multiple foci found in 62.0%
cases, with similar findings found in 17.1% cases on
Gadolinium-enhancing MRI. Multiple foci were most
seen in the periventricular region (44.8%) followed by
the juxta-cortical region (43.6%). Data was collected
on past and present treatment received by the patients.
Patients had commonly been prescribed with oral and
intravenous steroids (55.8%, 43.6%) and azathioprine
was found to be the most common disease modifying
therapy (DMT) prescribed in the past (30.7%).
Rituximab (3.1%), per oral steroids (1.2%), beta
interferon 1A (1.2%), and azathioprine (1.2%) were the
most common treatments prescribed as current
management. The most common disease complication
highlighted by this study is MS exacerbation which
occurred in 8.6% of the patients. This study has
limitations in the data collected as it does not include
disease progression with treatment however its
strengths lie in its extensive data collection related to
some neglected aspects of MS epidemiology, MRI
features and management in Pakistan.

Sindh Institute of Urology & Transplantation
(SIUT), Karachi
Rituximab is a monoclonal antibody which is widely
administered off label for MS treatment as it is well
tolerated and has a favorable cost effectiveness profil.7
There is ongoing data collection since 2017 of patients
diagnosed with MS presenting to Sindh Institute of
Urology & Transplantation (SIUT), Karachi. To date,
there are 55 patients with MS with their age ranging
from 18 to 55. All patients have been treated with
rituximab. The maximum number of doses of rituximab
given to a patient is 8. This DMT has shown
encouraging disease outcomes in this population for
example one patient’s expanded disability status scale
(EDSS) has improved from 4.5 to 2 since the start of
treatment with rituximab. The current data presented
has limitations as it does not include patient
demographics, disease progression and MRI findings
however it does highlight the vital role played by
rituximab in patients with MS in Pakistan.
Dr. Ruth K. M. Pfau Civil Hospital, Karachi
Data was collected from July 2018 till June 2021 on
patients presenting with demyelinating diseases to the
neurology department of Dr. Ruth K. M. Pfau Civil
Hospital, Karachi. Patients were diagnosed with either
MS, CIS or NMOSD. 27 patients were diagnosed with
MS. The age of the patients varied from 14 to 49 with
a median age of 26. The most common clinical
presentation was cranio-optico-spinal (26%) followed
by cranio-spinal (22%). Relapsing remitting MS was the
most common type of MS (67%) followed by primary
progressive MS (22%). Patients were prescribed
azathioprine
(44.4%),
mitoxantrone
(37.0%),
ocrelizumab (14.8%) and cyclophosphamide (3.7%).
All patients presenting with acute presentation of MS
were administered with pulse steroids. Disease
progression was measured in patients who had been
prescribed with treatment for at least 6 months.

Pakistan Institute of Medical Sciences, Islamabad
An extensive review was carried out on CNS
demyelinating diseases from January 2017 till
December 2021 at Pakistan Institute of Medical
Sciences, Islamabad (PIMS). The study was done
retrospectively as well as prospectively during this time.
Patients diagnosed with MS according to the
McDonald’s criteria and 12 years and older were
included (6). Other CNS demyelinating disorders
included in this study were clinically isolated syndrome
(CIS), neuromyelitis Optica spectrum disorders
(NMOSD) and Acute disseminated encephalomyelitis
(ADEM). 142 patients of MS were included in the
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Considering radiological representation of the disease
and EDSS, 55% of the patients showed improvement in
disease progression whereas 15% of the patients
deteriorated including one death due to drug induced
neutropenic sepsis. 30% of the patients showed no
change in the course of the disease after a minimum of
6 months of treatment. Although the study presents a
small cohort, it extensively presents data on disease
presentation and treatment outcome.

There are currently 9 patients of MS included in the
study with relapsing remitting MS as the most common
type of presentation (89%). Paraparesis has been the
most common symptom (44%) followed by visual
impairment (33.3%), sensory impairment (33.3%) and
ataxia (33.3%). MRI of the brain and spinal cord
represents typical findings of MS in 78% of the
patients. All patients are given two doses of 300mg of
ocrelizumab, 14 days apart followed by a 600 mg dose
after 6 months. Patients are then given subsequent
doses every 6 months. Patients are evaluated before
receiving treatment and then three, 6 and 12 months
after the initiation of treatment. Their clinical status is
measured by EDSS. The median EDSS before receiving
ocrelizumab is 7.5 compared to a median score of 4
after a year of treatment. No significant adverse effects
have been reported however two patients have
complained of nausea while receiving treatment. This
ongoing study provides immense information on
ocrelizumab as a treatment for patients with MS in
Pakistan. Although the study sample is comparatively
low, new patients are currently being enrolled into the
study including 6 patients who have already received
their first dose of ocrelizumab.

Sheikh Khalifah Bin Zayyad Hospital, Bolan
Medical Complex Hospital,
Sultan Tareen
Hospital, Quetta
Ocrelizumab is a Food and Drug Administration (FDA)
approved monoclonal antibody for MS. It is generally
well tolerated and highly efficacious DMT.8 A
prospective study is being carried out on patients
diagnosed with MS presenting to three hospitals in
Quetta including Sheikh Khalifah Bin Zayyad Hospital,
Bolan Medical Complex Hospital and Sultan Tareen
Hospital. The objective of this study is to assess the
efficacy and disease progression in patients with MS
receiving ocrelizumab. Patients diagnosed with MS
aged 16 years and older are included in the study.
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CONCLUSION
New research is exploring the characteristics of MS in
Pakistan with increased focus on treatment and
outcome of the disease in the country. It is unveiling
the barriers to disease diagnosis and management in
the country. However, there is no population-based
study to determine the prevalence or incidence of MS
in Pakistan. The PAKTRIMS conference was able to set

the stage for the announcement of the launch of the
Multiple Sclerosis Pakistan Registry which is an online
application-based registry, compatible with android and
iOS and aims to collect data of one thousand MS
patients across the country in the span of one year.
This will hopefully present a clearer picture of the
disease in the country.
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